Literature DB >> 23271822

High-flow oxygen administration by nasal cannula for adult and perinatal patients.

Jeffrey J Ward1.   

Abstract

The nasal cannula has been a commonly used patient interface to provide supplemental oxygen since its introduction in the 1940s. Traditionally, it has been categorized as a low-flow device and capable of delivering a 0.4 F(IO(2)) with flows up to 6 L/min to adults with normal minute ventilation. However, there is considerable performance variability among patients and design, which results in an exponential decline in delivered F(IO(2)) as breathing frequencies increase. The nasal cannula has also been successfully adapted for use in perinatal and pediatric respiratory care; flows are reduced, in the range of 0.25-1 L/min, due to smaller minute volumes. A decade or so ago, high-flow nasal cannula (HFNC) oxygen therapy was introduced, accompanied by heated humidification systems to prevent the associated drying of upper airway mucosa and to increase patient comfort. Therapeutic flows for adults were in the 15-40 L/min range; F(IO(2)) could be independently adjusted with air/O(2) blending. The HFNC has also found additional clinical application in perinatal care, as delivery systems with flows > 2 L/min could create a distending pressure similar to nasal CPAP. There is a small but growing body of information from clinical trials that supports use of HFNC as an alternative oxygen interface for adults who present with moderate hypoxemia that persists after receiving oxygen by reservoir-bag masks or similar therapy. Clinical observations report greater patient acceptance and comfort versus oxygen masks. HFNC therapy has also been considered valuable in perinatal care in treating the respiratory distress syndrome or supporting patients after extubation similar to nasal CPAP. At present, research-based evidence for the role of HFNC for its perinatal applications remains unclear. This review will identify proposed mechanisms for therapeutic effectiveness, current delivery equipment, guidelines for rational patient application, and direction for further research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23271822     DOI: 10.4187/respcare.01941

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  44 in total

1.  [High-flow oxygen therapy in hypoxic respiratory failure : Possible alternative to noninvasive ventilation].

Authors:  B Schönhofer
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-11-18       Impact factor: 0.840

2.  Application of an inline dry powder inhaler to deliver high dose pharmaceutical aerosols during low flow nasal cannula therapy.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  Int J Pharm       Date:  2018-05-05       Impact factor: 5.875

3.  Development of a High-Flow Nasal Cannula and Pharmaceutical Aerosol Combination Device.

Authors:  Benjamin M Spence; Worth Longest; Xiangyin Wei; Sneha Dhapare; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-03-11       Impact factor: 2.849

4.  Development of high efficiency ventilation bag actuated dry powder inhalers.

Authors:  Srinivas R B Behara; P Worth Longest; Dale R Farkas; Michael Hindle
Journal:  Int J Pharm       Date:  2014-02-07       Impact factor: 5.875

5.  Efficient Nose-to-Lung (N2L) Aerosol Delivery with a Dry Powder Inhaler.

Authors:  P Worth Longest; Laleh Golshahi; Srinivas R B Behara; Geng Tian; Dale R Farkas; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-09-05       Impact factor: 2.849

6.  Efficient Nose-to-Lung Aerosol Delivery with an Inline DPI Requiring Low Actuation Air Volume.

Authors:  Dale Farkas; Michael Hindle; P Worth Longest
Journal:  Pharm Res       Date:  2018-08-21       Impact factor: 4.200

7.  FIRST, DO NO HARM: A Response to "Oral Alimentation in Neonatal and Adult Populations Requiring High-Flow Oxygen via Nasal Cannula".

Authors:  Pamela Dodrill; Memorie Gosa; Suzanne Thoyre; Catherine Shaker; Britt Pados; Jinhee Park; Nicole DePalma; Keith Hirst; Kara Larson; Jennifer Perez; Kayla Hernandez
Journal:  Dysphagia       Date:  2016-07-19       Impact factor: 3.438

8.  Randomized Trial of Apneic Oxygenation during Endotracheal Intubation of the Critically Ill.

Authors:  Matthew W Semler; David R Janz; Robert J Lentz; Daniel T Matthews; Brett C Norman; Tufik R Assad; Raj D Keriwala; Benjamin A Ferrell; Michael J Noto; Andrew C McKown; Emily G Kocurek; Melissa A Warren; Luis E Huerta; Todd W Rice
Journal:  Am J Respir Crit Care Med       Date:  2016-02-01       Impact factor: 21.405

9.  Oral Alimentation in Neonatal and Adult Populations Requiring High-Flow Oxygen via Nasal Cannula.

Authors:  Steven B Leder; Jonathan M Siner; Matthew J Bizzarro; Brian M McGinley; Maureen A Lefton-Greif
Journal:  Dysphagia       Date:  2015-11-21       Impact factor: 3.438

10.  Nasal high-flow preoxygenation for endotracheal intubation in the critically ill patient: a randomized clinical trial.

Authors:  Christophe Guitton; Stephan Ehrmann; Christelle Volteau; Gwenhael Colin; Adel Maamar; Vanessa Jean-Michel; Pierre-Joachim Mahe; Mickael Landais; Noelle Brule; Cedric Bretonnière; Olivier Zambon; Mickael Vourc'h
Journal:  Intensive Care Med       Date:  2019-01-21       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.